AKTS (Aktis Oncology) Total Assets: $576.80 Mil (As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.76
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Total Assets?

Aktis Oncology AKTS +2.82% 9 Total Assets is $576.80 Mil as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

Aktis Oncology's Total Assets for the quarter that ended in Mar. 2026 was $576.80 Mil.

During the past 12 months, Aktis Oncology's average Total Assets Growth Rate was 32.10% per year. During the past 3 years, the average Total Assets Growth Rate was 57.60% per year.

During the past 4 years, Aktis Oncology's highest 3-Year average Total Assets Growth Rate was 57.60%. The lowest was 57.60%. And the median was 57.60%.

Total Assets is connected with ROA %. Aktis Oncology's annualized ROA % for the quarter that ended in Mar. 2026 was -17.42%. Total Assets is also linked to Revenue through Asset Turnover. Aktis Oncology's Asset Turnover for the quarter that ended in Mar. 2026 was 0.01.

Aktis Oncology  (NAS:AKTS) Total Assets Explanation

Total Assets is connected with ROA %.

Aktis Oncology's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-73.3/( (264.885+576.801)/ 2 )
=-73.3/420.843
=-17.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aktis Oncology's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=3.227/( (264.885+576.801)/ 2 )
=3.227/420.843
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aktis Oncology Total Assets Related Terms

Aktis Oncology Total Assets Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Total Assets Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Assets
138.32 122.36 326.18 264.89

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial 326.18 0.00 279.04 264.89 576.80
AKTS
9GF Score
Aktis Oncology Inc AKTS
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aktis Oncology's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-146.149+411.034
=264.89

Aktis Oncology's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=506.108+70.693
=576.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $576.80 Mil mean?
Aktis Oncology (AKTS) has a Total Assets of $576.80 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Total Assets too high?
Aktis Oncology's current Total Assets is $576.80 Mil. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Total Assets compare to ZBIO and MLTX?
Aktis Oncology's Total Assets of $576.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Total Assets is $576.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Total Assets of $576.80 Mil. The current Total Assets is $576.80 Mil. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Total Assets is $576.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.76
Price